Excellergy

Excellergy is a biotechnology company dedicated to developing a first-class portfolio of trifunctional Effector Cell Response Inhibitors (ECRI) to combat severe allergic diseases and help improve patients' quality of life. By leveraging clinically validated immunoglobulin E (IgE) biology and novel ECRI pharmacology, Excellergy is surpassing traditional anti-IgE approaches by directly targeting the source of allergic signaling — IgE bound to effector cells.